Format

Send to

Choose Destination
Clin Psychopharmacol Neurosci. 2014 Apr;12(1):19-30. doi: 10.9758/cpn.2014.12.1.19. Epub 2014 Apr 24.

Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

Author information

1
Department of Psychiatry, Kyung Hee University School of Medicine, Seoul, Korea.
2
Department of Life Sciences, Ewha Womans University, Seoul, Korea.
3
Department of Psychiatry, Dankook University Medical College, Chungnam, Korea.
4
Kyung Hee University School of Medicine, Seoul, Korea.
5
Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.
6
Department of Pharmacology, Konkuk University School of Medicine, Seoul, Korea.
7
Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.

Abstract

In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.

KEYWORDS:

Child development disorders, pervasive; Drug therapy; Etiology

Supplemental Content

Full text links

Icon for Korean College of Neuropsychopharmacology Icon for PubMed Central
Loading ...
Support Center